| [Refractory epilepsy: use of the new definition and related risk factors. A study in the Mexican population of a third-level centre]. | |
| | |
MedLine Citation:
|
PMID: 22278892 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: The International League against Epilepsy (ILAE) has recently proposed a consensus to define refractory epilepsy. PATIENTS AND METHODS: A retrospective, analytical, descriptive study was conducted involving 206 patients who were attended at the epilepsy clinic of a third-level centre in Mexico. The ILAE's new definition of pharmacoresistance was used to classify the patients. The frequency and risk factors involved in the refractoriness were reported. The tendency to prescribe antiepileptic drugs (AED) in this population was analysed using secondary data. RESULTS: Of the 206 patients analysed, 57 (28%) were free of seizures, 115 (56%) continued to have seizures, 17 (8%) were classified as undetermined and 17 (8%) were pseudo-refractory. The statistically significant factors associated to pharmaco-resistance that were found in our population were: focal versus generalised epilepsy (p = 0.02), catamenial epilepsy (p = 0.02), abnormal psychomotor development (p = 0.02), history of epilepsy in the family (p = 0.025), neurological examination with focal abnormality (p = 0.04), perinatal hypoxia (p = 0.06) and prior psychiatric illness (p = 0.03). The mostly frequently AED used in mono- and polytherapy were valproate and carbamazepine. Of all the patients who were free of seizures, 47% were treated using monotherapy. CONCLUSIONS: The frequency of pharmacoresistance in the population analysed was estimated to be 56%. Identification of the factors associated with pharmacoresistance makes it possible to consider surgical treatment or to optimise the treatment with AED. There is a tendency to use the new AED, above all in combination therapy. Our findings are consistent with those described in the literature. |
| | |
Authors:
|
Iris E Martínez-Juárez; Rosario López-Zapata; Bety Gómez-Arias; Erandi Bravo-Armenta; Liliana Romero-Ocampo; Zuleika Estévez-Cruz; Griega Hernández-De la Cruz; Saulo Morán-Molina |
Publication Detail:
|
Type: English Abstract; Journal Article |
Journal Detail:
|
Title: Revista de neurologia Volume: 54 ISSN: 1576-6578 ISO Abbreviation: Rev Neurol Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-26 Completed Date: 2012-05-25 Revised Date: 2012-08-31 |
Medline Journal Info:
|
Nlm Unique ID: 7706841 Medline TA: Rev Neurol Country: Spain |
Other Details:
|
Languages: spa Pagination: 159-66 Citation Subset: IM |
Affiliation:
|
Instituto de Neurologia y Neurocirugia de Mexico, DF Mexico. imartinez@innn.edu.mx |
Vernacular Title:
|
Epilepsia farmacorresistente: uso de la nueva definición y factores de riesgo relacionados. Estudio en poblacion mexicana de un centro de tercer nivel. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anticonvulsants / therapeutic use Drug Resistance / physiology* Epilepsy / diagnosis*, drug therapy, physiopathology* Female Humans Male Mexico Middle Aged Outpatient Clinics, Hospital* Retrospective Studies Risk Factors Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Anticonvulsants |
| Comments/Corrections | |
Comment In:
|
Rev Neurol. 2012 Jul 16;55(2):128
[PMID:
22760776
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [Care for patients with acute stroke: effectiveness of portable vesical ultrasound imaging in the st...
Next Document: [Treatment of neuropathic pain with lacosamide].